Jin Yang Pharmaceutical Past Earnings Performance
Past criteria checks 5/6
Jin Yang Pharmaceutical has been growing earnings at an average annual rate of 36.5%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 18.6% per year. Jin Yang Pharmaceutical's return on equity is 23.8%, and it has net margins of 25.3%.
Key information
36.5%
Earnings growth rate
37.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 18.6% |
| Return on equity | 23.8% |
| Net Margin | 25.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Jin Yang Pharmaceutical's (KOSDAQ:007370) Problems Go Beyond Weak Profit
May 23
We're Not So Sure You Should Rely on Jin Yang Pharmaceutical's (KOSDAQ:007370) Statutory Earnings
Dec 17Recent updates
Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370) Shares Fly 32% But Investors Aren't Buying For Growth
Aug 19These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt Reasonably Well
Aug 12Jin Yang Pharmaceutical's (KOSDAQ:007370) Problems Go Beyond Weak Profit
May 23A Look At The Intrinsic Value Of Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370)
Mar 22Here's Why I Think Jin Yang Pharmaceutical (KOSDAQ:007370) Is An Interesting Stock
Mar 04These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt Safely
Feb 11
Are Jin Yang Pharmaceutical Co., Ltd.'s (KOSDAQ:007370) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Jan 21Does Jin Yang Pharmaceutical's (KOSDAQ:007370) Share Price Gain of 49% Match Its Business Performance?
Jan 04We're Not So Sure You Should Rely on Jin Yang Pharmaceutical's (KOSDAQ:007370) Statutory Earnings
Dec 17Here's Why We Think Jin Yang Pharmaceutical (KOSDAQ:007370) Is Well Worth Watching
Nov 30Revenue & Expenses Breakdown
How Jin Yang Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 111,149 | 28,132 | 60,081 | 0 |
| 30 Jun 24 | 103,601 | 9,807 | 56,499 | 0 |
| 31 Mar 24 | 99,168 | 11,766 | 53,148 | 0 |
| 31 Dec 23 | 94,111 | 12,659 | 47,851 | 0 |
| 30 Sep 23 | 87,806 | 12,951 | 41,946 | 0 |
| 30 Jun 23 | 85,546 | 15,219 | 39,101 | 0 |
| 31 Mar 23 | 80,973 | 13,352 | 36,320 | 0 |
| 31 Dec 22 | 76,264 | 12,308 | 34,031 | 0 |
| 30 Sep 22 | 74,991 | 12,234 | 31,802 | 0 |
| 30 Jun 22 | 68,782 | 8,124 | 29,094 | 0 |
| 31 Mar 22 | 66,746 | 8,839 | 27,558 | 0 |
| 31 Dec 21 | 62,839 | 9,538 | 26,583 | 0 |
| 30 Sep 21 | 58,680 | 11,016 | 24,212 | 0 |
| 30 Jun 21 | 54,927 | 10,270 | 22,309 | 0 |
| 31 Mar 21 | 51,099 | 7,307 | 21,959 | 0 |
| 31 Dec 20 | 49,525 | 5,229 | 21,647 | 0 |
| 30 Sep 20 | 49,786 | 2,465 | 24,019 | 0 |
| 30 Jun 20 | 48,197 | 926 | 24,431 | 0 |
| 31 Mar 20 | 47,879 | 718 | 24,413 | 0 |
| 31 Dec 19 | 47,351 | 1,647 | 23,945 | 0 |
| 30 Sep 19 | 47,691 | 1,354 | 23,943 | 0 |
| 30 Jun 19 | 48,903 | 2,042 | 24,460 | 0 |
| 31 Mar 19 | 47,577 | 2,119 | 23,750 | 0 |
| 31 Dec 18 | 46,863 | 933 | 23,991 | 0 |
| 30 Sep 18 | 44,319 | -5,353 | 28,812 | 0 |
| 30 Jun 18 | 43,858 | -5,349 | 27,967 | 0 |
| 31 Mar 18 | 43,815 | -5,724 | 28,257 | 0 |
| 31 Dec 17 | 43,450 | -5,768 | 27,854 | 0 |
| 30 Sep 17 | 42,432 | -6,372 | 29,173 | 0 |
| 30 Jun 17 | 40,902 | -7,054 | 28,785 | 0 |
| 31 Mar 17 | 40,833 | -7,242 | 28,154 | 0 |
| 31 Dec 16 | 36,132 | -9,099 | 26,986 | 0 |
| 30 Sep 16 | 36,191 | -3,674 | 21,095 | 0 |
| 30 Jun 16 | 35,729 | -3,538 | 21,724 | 0 |
| 31 Mar 16 | 35,400 | -3,948 | 22,573 | 0 |
| 31 Dec 15 | 40,149 | -1,004 | 23,074 | 0 |
| 30 Sep 15 | 44,388 | 3,058 | 21,923 | 0 |
| 30 Jun 15 | 46,246 | 3,311 | 22,778 | 0 |
| 31 Mar 15 | 46,690 | 4,099 | 22,390 | 0 |
| 31 Dec 14 | 45,237 | 4,013 | 21,636 | 0 |
| 30 Sep 14 | 44,428 | 4,333 | 19,924 | 0 |
| 30 Jun 14 | 43,379 | 5,501 | 18,667 | 0 |
| 31 Mar 14 | 40,458 | 4,727 | 18,519 | 0 |
| 31 Dec 13 | 40,235 | 4,193 | 18,949 | 0 |
Quality Earnings: A007370 has a high level of non-cash earnings.
Growing Profit Margin: A007370's current net profit margins (25.3%) are higher than last year (14.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A007370's earnings have grown significantly by 36.5% per year over the past 5 years.
Accelerating Growth: A007370's earnings growth over the past year (117.2%) exceeds its 5-year average (36.5% per year).
Earnings vs Industry: A007370 earnings growth over the past year (117.2%) exceeded the Pharmaceuticals industry 21.9%.
Return on Equity
High ROE: A007370's Return on Equity (23.8%) is considered high.